Table 3.
Mean Values for Economic Measures from the PROTECT II Trial
| Economic variables | Treatment | |||
|---|---|---|---|---|
| Index admissions, all cases | IABP (N = 211) | pVAD (N = 216) | Difference | P valuea |
| Total charge | $124,778 | $154,470 | $29,692 | <.001 |
| Total cost | $33,684 | $47,667 | $13,983 | <.001 |
| LOS, days | 7.4 | 7.1 | −0.30 | .331 |
| Readmissions, all casesb | IABP (N = 100) | pVAD (N = 108) | Difference | |
| Total charge | $102,261 | $35,856 | −$66,405 | <.001 |
| Total cost | $21,834 | $11,007 | −$10,827 | <.001 |
| LOS, days | 7.0 | 5.0 | −2.0 | <.001 |
| EOC, all casesc | IABP (N = 211) | pVAD (N = 216) | Difference | |
| Total charge | $172,758 | $172,564 | −$194 | .785 |
| Total cost | $44,032 | $53,171 | $9139 | <.001 |
| LOS, daysd | 10.7 | 9.6 | −1.10 | .026 |
P values derived from the nonparametric Mann-Whitney test. Statistical significance is reached when P <.050.
Readmission sample size (N) represents the total number of readmissions, not the total number of study subjects that experienced at least 1 readmission.
The pVAD case cost reflects costs derived for actual billed charges. For the incremental cost-effectiveness ratio model, pVAD's index and EOC costs were increased by approximately $5000 to align the study data with the actual hospital acquisition cost for the pVAD as reported by the manufacturer.
The median values for EOC LOS are 9 days for IABP and 7 days for pVAD (P = .008).
EOC indicates episode of care; IABP, intra-aortic balloon pump; LOS, length of stay; pVAD, percutaneous ventricular assist device.